



Cite this as: *BMJ* 2022;378:o1713
<http://dx.doi.org/10.1136/bmj.o1713>
Published: 13 July 2022

Update to living WHO guideline on drugs for covid-19

This living guideline by Agarwal and colleagues (*BMJ* 2020;370:m3379) has been updated. For the latest update, visit doi:. The latest version of this WHO living guidance provides two new recommendations for patients with non-severe covid-19: (a) a recommendation against the use of fluvoxamine except in the context of a clinical trial; (b) a strong recommendation against the use of colchicine. No recommendation was made for either drug in patients with severe or critical illness, given limited or no data.